Abstract
The mdm2 oncogene product, MDM2, is an ubiquitin protein ligase that inhibits the transcriptional activity of the tumor suppressor p53 and promotes its degradation. About 50% of all human cancers present mutations or deletions in the TP53 gene. In the remaining half of all human neoplasias that express the wild-type protein, aberrations of p53 regulators, such as MDM2, account for p53 inhibition. For this reason, designing small-molecule inhibitors of the p53-MDM2 protein-protein interaction is a promising strategy for the treatment of cancers retaining wild-type p53. The development of inhibitors has been challenging. Although many small-molecule MDM2 inhibitors have shown potent in vitro activity, only a limited number of compounds have demonstrated to possess acceptable pharmacokinetic properties for in vivo evaluation. To date, the most studied chemotypes have been cis-imidazolines (such as nutlins), benzodiazepines, and spiro-oxindoles. The cis-imidazolines were the first discovered potent and selective small-molecule inhibitors of the p53- MDM2 interaction, and they continue to show therapeutic potential. This review will focus on recent molecular modeling approaches (molecular dynamics, pharmacophore-based, molecular docking, structure-based design) used with the aim to better understand the behavior of these proteins and to discover new small-molecule inhibitors of the p53-MDM2 protein-protein interaction for the treatment of cancer.
Keywords: p53-MDM2 interaction, molecular dynamics, pharmacophore-based approaches, molecular docking, structurebased design
Current Medicinal Chemistry
Title: Molecular Modeling Approaches in the Discovery of New Drugs for Anti-Cancer Therapy: The Investigation of p53-MDM2 Interaction and its Inhibition by Small Molecules
Volume: 17 Issue: 28
Author(s): A. Lauria, M. Tutone, M. Ippolito, L. Pantano and A. M. Almerico
Affiliation:
Keywords: p53-MDM2 interaction, molecular dynamics, pharmacophore-based approaches, molecular docking, structurebased design
Abstract: The mdm2 oncogene product, MDM2, is an ubiquitin protein ligase that inhibits the transcriptional activity of the tumor suppressor p53 and promotes its degradation. About 50% of all human cancers present mutations or deletions in the TP53 gene. In the remaining half of all human neoplasias that express the wild-type protein, aberrations of p53 regulators, such as MDM2, account for p53 inhibition. For this reason, designing small-molecule inhibitors of the p53-MDM2 protein-protein interaction is a promising strategy for the treatment of cancers retaining wild-type p53. The development of inhibitors has been challenging. Although many small-molecule MDM2 inhibitors have shown potent in vitro activity, only a limited number of compounds have demonstrated to possess acceptable pharmacokinetic properties for in vivo evaluation. To date, the most studied chemotypes have been cis-imidazolines (such as nutlins), benzodiazepines, and spiro-oxindoles. The cis-imidazolines were the first discovered potent and selective small-molecule inhibitors of the p53- MDM2 interaction, and they continue to show therapeutic potential. This review will focus on recent molecular modeling approaches (molecular dynamics, pharmacophore-based, molecular docking, structure-based design) used with the aim to better understand the behavior of these proteins and to discover new small-molecule inhibitors of the p53-MDM2 protein-protein interaction for the treatment of cancer.
Export Options
About this article
Cite this article as:
Lauria A., Tutone M., Ippolito M., Pantano L. and Almerico M. A., Molecular Modeling Approaches in the Discovery of New Drugs for Anti-Cancer Therapy: The Investigation of p53-MDM2 Interaction and its Inhibition by Small Molecules, Current Medicinal Chemistry 2010; 17 (28) . https://dx.doi.org/10.2174/092986710792232021
DOI https://dx.doi.org/10.2174/092986710792232021 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
13C Metabolic Flux Analysis: From the Principle to Recent Applications
Current Bioinformatics Supervised Machine Learning Algorithms for Evaluation of Solid Lipid Nanoparticles and Particle Size
Combinatorial Chemistry & High Throughput Screening The “Epigenetic Code Replication Machinery”, ECREM: A Promising Drugable Target of the Epigenetic Cell Memory
Current Medicinal Chemistry Correlation between Antioxidant/Antimutagenic and Antiproliferative Activity of Some Phytochemicals
Anti-Cancer Agents in Medicinal Chemistry Peironimev-Plus® in the Treatment of Chronic Inflammation of Tunica Albuginea (Peyronie’s Disease). Results of a Controlled Study
Inflammation & Allergy - Drug Targets (Discontinued) Cationized Albumin Conjugated Solid Lipid Nanoparticles as Vectors for Brain Delivery of an Anti-Cancer Drug
Current Nanoscience Backbone-Cyclized Peptides: A Critical Review
Current Topics in Medicinal Chemistry Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Current Cancer Drug Targets CD93: Recent Advances and Implications in Disease
Current Drug Targets Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Vesicle Trafficking, Autophagy and Nanoparticles: A Brief Review
Current Nanomedicine A Comparison of the Inhibitory Effects of Anti-Cancer Drugs on Thioredoxin Reductase and Glutathione S-Transferase in Rat Liver
Anti-Cancer Agents in Medicinal Chemistry Diosmetin Induces Apoptosis by Downregulating AKT Phosphorylation via P53 Activation in Human Renal Carcinoma ACHN Cells
Protein & Peptide Letters Monoclonal Antibodies in the Management of Solid Tumors
Current Topics in Medicinal Chemistry Supercritical Fluid Extraction of Bioactive Compounds from Botanic Matrices: Experimental Data, Process Parameters and Economic Evaluation
Recent Patents on Engineering Progress of Biological Agents on Psoriatic Arthritis
Current Pharmaceutical Biotechnology Applications of Nanomaterials for Cancer Treatment: Recent Patents Review
Recent Patents on Nanomedicine Life or Death of T Cells with Antigen-Specific Receptors - Using T Cells for Cancer Adoptive Immunotherapy / Gene Therapy
Current Gene Therapy Dual-modality Chemo-photodynamic Therapy Using RB and DOX as Anti-cancer Drugs by PAMAM-grafted Hollow Porous Silica Nanoparticles
Current Nanoscience MEMS and Microfluidics for Diagnostics Devices
Current Pharmaceutical Biotechnology